Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease

Stroke

Volumn 43, Issue 2, 2012, Pages 571-574

  McDonald, David A ^a   Shi, Changbin ^b   Shenkar, Robert ^b   Stockton, Rebecca A ^c   Liu, Feifei ^b   Ginsberg, Mark H ^c   Marchuk, Douglas A ^a   Awad, Issam A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

cavernous angioma; cerebral cavernous malformation; fasudil; ROCK; therapy

Indexed keywords

FASUDIL; PHOSPHATASE; PHOSPHATASE MYOSIN PHOSPHATASE TARGET 1; PLACEBO; RHO KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN HEMORRHAGE; CAVERNOUS HEMANGIOMA; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; ENCEPHALITIS; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENOTYPE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BRAIN; CEREBRAL HEMORRHAGE; ENZYME INHIBITORS; INFLAMMATION; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; MICE; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS; MUTS HOMOLOG 2 PROTEIN; PHENOTYPE; PROTO-ONCOGENE PROTEINS; RHO-ASSOCIATED KINASES; TUMOR SUPPRESSOR PROTEIN P53; VASODILATOR AGENTS;

EID: 84856426329     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.625467     Document Type: Article

References (15)

1. Laberge-le Couteulx S, Jung HH, Labauge P, Houtteville JP, Lescoat C, Cecillon M, et al. Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet. 1999;23:189-193. (Pubitemid 29455391)
2. Sahoo T, Johnson EW, Thomas JW, Kuehl PM, Jones TL, Dokken CG, et al. Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum Mol Genet. 1999;8:2325-2333. (Pubitemid 29525349)
3. Glading A, Han J, Stockton RA, Ginsberg MH. KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell cell junctions. J Cell Biol. 2007; 179:247-254. (Pubitemid 350004889)
4. Stockton RA, Shenkar R, Awad IA, Ginsberg MH. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med. 2010;207:881-896.
5. Gault J, Awad IA, Recksiek P, Shenkar R, Breeze R, Handler M, et al. Cerebral cavernous malformations: somatic mutations in vascular endothelial cells. Neurosurgery. 2009;65:138-145.
6. Akers AL, Johnson E, Steinberg GK, Zabramski JM, Marchuk DA. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet. 2009;18:919-930.
7. Pagenstecher A, Stahl S, Sure U, Felbor U. A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet. 2009;18: 911-918.
8. McDonald DA, Shenkar R, Shi C, Stockton RA, Akers AL, Kucherlapati MH, et al. A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet. 2011;20:211-222.
9. Shenkar R, Venkatasubramanian PN, Wyrwicz AM, Zhao JC, Shi C, Akers A, et al. Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models. Neurosurgery. 2008;63:790-798.
10. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95-105.
11. Yamaguchi H, Kasa M, Amano M, Kaibuchi K, Hakoshima T. Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. Structure. 2006;14:589-600. (Pubitemid 43363491)
12. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50:17-24. (Pubitemid 47220442)
13. Hata T, Goto C, Soga J, Hidaka T, Fujii Y, Idei N, et al. Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. Atherosclerosis. 2011;214:117-121.
14. Whitehead KJ, Chan AC, Navankasattusas S, Koh W, London NR, Ling J, et al. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med. 2009;15:177-184.
15. Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, et al. Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. J Biol Chem. 2010;285:11760-11764.